TechConnect Innovation Program

Compounds for the Treatment of Alzheimer's Disease by Inhibiting Interaction of Amyloid Beta Peptide and Amyloid binding alcohol dehydrogenase (ABAD)

University of Kansas, KS, United States

TECHNOLOGY SUMMARY

A novel class of small molecule Aβ-ABAD interaction inhibitors for the treatment of Alzheimer's Disease

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: The compounds inhibited Aβ-ABAD interaction with high specificity and demonstrated attractive drug-like properties - including absorption, toxicity, blood brain barrier penetration, and potency.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 13M

Website: www.kuic.ku.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: Federal Grant, University

Looking for: Both Funding and Development Partners